Free tool
FAERS Monitor: Restoril
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018163 or its brand name (Restoril, Temazepam). Reports on generic versions are filed under their own applications.
Reports
37,909
Serious
28,415
75% of reports
Hospitalization
12,655
Death reported
7,674
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue2,856
- drug ineffective2,480
- nausea2,454
- pain2,332
- headache2,331
- toxicity to various agents2,306
- diarrhoea1,841
- dyspnoea1,792
- insomnia1,707
- death1,701
- dizziness1,691
- off label use1,683
- fall1,667
- anxiety1,532
- asthenia1,466
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 841 |
| 2005 | 965 |
| 2006 | 1,079 |
| 2007 | 922 |
| 2008 | 924 |
| 2009 | 1,231 |
| 2010 | 1,588 |
| 2011 | 1,536 |
| 2012 | 1,790 |
| 2013 | 1,473 |
| 2014 | 1,664 |
| 2015 | 2,614 |
| 2016 | 2,850 |
| 2017 | 2,573 |
| 2018 | 2,626 |
| 2019 | 2,570 |
| 2020 | 2,378 |
| 2021 | 1,862 |
| 2022 | 1,352 |
| 2023 | 1,427 |
| 2024 | 1,528 |
| 2025 | 1,173 |
| 2026 | 941 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,016,250 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| toxicity to various agentsSignal | 2,306 | 7.7 | 7.4 | 13,311 |
| insomniaSignal | 1,707 | 3.6 | 3.4 | 3,179 |
| anxietySignal | 1,532 | 3.0 | 2.9 | 2,054 |
| fallSignal | 1,667 | 2.8 | 2.7 | 1,931 |
| astheniaSignal | 1,466 | 2.2 | 2.1 | 934 |
| painSignal | 2,332 | 2.1 | 2.0 | 1,397 |
| headacheSignal | 2,331 | 2.1 | 2.0 | 1,317 |
| fatigueSignal | 2,856 | 2.0 | 2.0 | 1,564 |
| dizziness | 1,691 | 1.9 | 1.8 | 715 |
| dyspnoea | 1,792 | 1.8 | 1.7 | 600 |
| nausea | 2,454 | 1.7 | 1.7 | 770 |
| diarrhoea | 1,841 | 1.6 | 1.5 | 407 |
| death | 1,701 | 1.1 | 1.0 | 15 |
| off label use | 1,683 | 1.1 | 1.0 | 7 |
| drug ineffective | 2,480 | 1.0 | 1.0 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.